Redeye reviews the Nanexa case in light of the recent development of NEX-20, its latest project NEX-22, and its collaboration with Novo Nordisk. We believe upcoming events regarding the clinical development of NEX-20 and NEX-22 bode well for the share price development, and that Nanexa’s investment agreement with Novo Nordisk could also generate shareholder value.